LN-606113
RIBOSTAMYCIN SULFATE SALT , 99.9% , 25546-65-0
Update time: 2023-04-23
PRODUCT Properties
| Melting point: | 192-195°; mp 175-180° (dec) |
| alpha | D23 +42° |
| Boiling point: | 561.28°C (rough estimate) |
| Density | 1.1751 (rough estimate) |
| refractive index | 1.6700 (estimate) |
| storage temp. | 2-8°C |
| pka | 7.70(at 25℃) |
Description and Uses
Ribostamycin was found in the culture broth of Streptomyces ribosidificus by Meiji Seika Kaisha in 1970 in the course of screening aminoglycoside antibiotics. It is structurally related to neomycin but lacks the diaminoidose (glucose) moiety substituted on the ribose moiety. Ribostamycin is much less toxic than neomycin and shows strong activity against a variety of gram-positive and gram-negative bacteria, except Pseudomonas aeruginosa. It is used parenterally for therapy of urinary tract, respiratory tract, surgical, and other infections.
Safety
| Hazard Codes | T |
| Risk Statements | 61-20/21/22 |
| Safety Statements | 53-22-36/37/39-45 |
| WGK Germany | 3 |
| RTECS | WK2300000 |
| Toxicity | mouse,LD50,intracrebral,66800ug/kg (66.8mg/kg),BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLDLUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION,Kiso to Rinsho. Clinical Report. Vol. 4, Pg. 2489, 1970. |
